Mackenzie Financial
TGTX icon

Mackenzie Financial’s TG Therapeutics TGTX Stock Holding History

Mackenzie Financial’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$441K Buy
+8,025
New +$328K ﹤0.01% 1347
2026
Q1 		– Sell
-9,101
Closed -$270K – 1749
2025
Q4 		$270K Sell
9,101
-441
-5% -$14.4K ﹤0.01% 1421
2025
Q3 		$345K Sell
9,542
-6,613
-41% -$218K ﹤0.01% 1362
2025
Q2 		$581K Buy
16,155
+568
+4% +$21.1K ﹤0.01% 1178
2025
Q1 		$615K Buy
15,587
+6,699
+75% +$225K ﹤0.01% 1132
2024
Q4 		$268K Sell
8,888
-7,609
-46% -$218K ﹤0.01% 1432
2024
Q3 		$386K Buy
16,497
+5,715
+53% +$125K ﹤0.01% 1090
2024
Q2 		$192K Hold
10,782
– – ﹤0.01% 1349
2024
Q1 		$164K Buy
+10,782
New +$172K ﹤0.01% 1372
2023
Q3 		– Sell
-18,788
Closed -$427K – 1593
2023
Q2 		$427K Buy
18,788
+6,053
+48% +$156K ﹤0.01% 1065
2023
Q1 		$192K Buy
+12,735
New +$193K ﹤0.01% 1353
2021
Q4 		– Sell
-7,487
Closed -$249K – 1498
2021
Q3 		$249K Buy
+7,487
New +$232K ﹤0.01% 1215
2020
Q4 		– Sell
-31,940
Closed -$855K – 1089
2020
Q3 		$855K Buy
+31,940
New +$735K ﹤0.01% 696

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Mackenzie Financial's TGTX Position: Q2 2026 in Review

Mackenzie Financial opened a new position in TG Therapeutics (TGTX) in Q2 2026: 8,025 shares worth $441K. The stake represents ﹤0.01% of the portfolio and ranks #1347 among its holdings. This is a return to the name: Mackenzie Financial previously reported a position in TGTX as recently as Q4 2025.

Mackenzie Financial first reported a position in TGTX in Q3 2020 and has held it in 13 quarters since. The position peaked at $855K in Q3 2020. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Mackenzie Financial held 8,025 shares of TG Therapeutics worth $441K as of Q2 2026.
  • TG Therapeutics was a new Mackenzie Financial position in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of Mackenzie Financial's portfolio in Q2 2026, its #1347 holding.
  • Mackenzie Financial first reported a position in TG Therapeutics in Q3 2020 and has held it in 13 quarters since.
  • Mackenzie Financial's TG Therapeutics position peaked at $855K in Q3 2020.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.